TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00283114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lintuzumab
Description: 1.5 - 8 mg/kg IV (in the vein) on Days 1, 8, 15, 22 and 29 of Cycle 1; 1.5 - 8 mg/kg IV (in the vein) every other week for all subsequent cycles
Study: NCT00071071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HuMax-CD4
Description: HuMax-CD4 280 mg was administered as a subcutaneous (SC) infusion once daily (OD) up to 18 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HuMax-CD4
Description: HuMax-CD4 560 mg was administered as a SC infusion OD up to 18 weeks.
Study: NCT00838331

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fresh blood
Description: For fresh transfusions, a whole blood unit will be drawn from volunteers, processed, and then reinfused on the same day during the study. For impaired and repaired transfusions, the volunteers will be brought to the blood bank to donate; then, after processing and the appropriate length of storage (eg, 28 days), they will return for the FBF studies. Since recipients of fresh transfusions are relatively anemic after donation and before reinfusion, recipients of impaired/repaired transfusions should also be mildly anemic for the study. Thus, they will donate another whole blood unit prior to beginning the study course, they will be transfused with their stored unit during the study, and then the autologous unit collected at the beginning of the day will be reinfused at the end of the day after the study is complete.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aged blood
Description: In a separate aim, the FMD assay will be used to investigate NO-mediated vasodilation in patients with CVD who are receiving transfusions. Over 60% of blood orders for cardiology patients at Emory are for 2 units or more. Therefore, when a 2-unit order is placed on a consented patient, they will be issued both fresh (\< 7 days) and impaired (\> 28 days) compatible units from inventory. Prior to starting transfusions, the patient will be randomized to either receive the fresh or the older unit first. All RBC units will be ACD/AS1. Units will also be leukoreduced and/or irradiated, if either of those modifications were found to impair NO bioavailability in prior studies. If washing or rejuvenation were found to be successful in significantly repairing NO bioavailability in previous aims, some patients may also receive impaired and repaired (\> 28 days; washed or rejuvenated) RBC transfusions.
Study: NCT01379274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide and azacitidine combination
Description: lenalidomide 10 mg will be administered orally on Days 1-28 of each 28-day cycle. Patients who fail to achieve an erythroid response per 2006 IWG criteria after 3 cycles of monotherapy will receive lenalidomide at the same dose administered in cycle 3 and low-dose azacitidine25 mg/m2 subcutaneously (SC) or intravenously (IV) for 5 days (on Days 1-5) of every 28-day cycle.~Patients who fail to respond (2006 IWG criteria) after receiving two cycles of combination therapy will receive lenalidomide at the same dose administered in Cycle 3 and azacitidine 50 mg/m2 SC or IV given daily on Days 1-5 of each 28-day cycle, if no grade 4 toxicity developed or no delay greater than 2 weeks in starting a new cycle was experienced during the first 2 cycles of combination therapy.
Study: NCT02638792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based exposure therapy (I-ET)
Description: The internet-based exposure therapy (I-ET) group receives a ten-week Internet-based CBT treatment, which is an extended version of the self-help book Sluta älta och grubbla med kognitiv beteendeterapi (How to quit worrying and ruminating with Cognitive behavior therapy) by licensed psychologist Olle Wadström (2007). The main focus of the book is to expose to the frightening word/image and refrain from using neutralizing thoughts. This is supposed to lead to the extinction of upsetting words/images.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based stress management therapy
Description: The I-SMT group receives a ten-week Internet-based CBT treatment focused on stress and how to manage stressful situations. This protocol is based on current evidence based recommendations for worry and has shown to be effective when delivered via the internet for irritable bowel syndrome and hypochondric worries.
Study: NCT02742038

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoride varnish plus education
Description: Biannual varnish every 6 month/ 24 months plus educational component

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride varnish plus education
Description: Biannual varnish every 6 month/ 24 months plus educational component
Study: NCT05011929

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: refer to the arm description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Description: refer to the arm description
Study: NCT03987503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epclusa (SOF/VEL)
Description: a trained physician will provide research participants with two-week supply of SOF/VEL. Treatment is: 1 tablet SOF/VEL (400 mg sofosbuvir/100 mg velpatasvir) daily x 12 weeks. The initial 2-week supply is provided by Gilead Sciences and will be dispensed to participants upon enrollment. Prescriptions and insurance prior authorizations for SOF/VEL will be submitted by the study pharmacist though the UCSF Specialty Pharmacy. The study team will be notified once insurance-authorized drug is available and will bring participants' medication in 2 supplies to the study site prior to study visits.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of HCV care provided by medical care provider

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fibroscan® 430 Mini Plus
Description: Trained research staff will measure participants liver stiffness using liver ultrasonographic elastography. Research staff place ultrasound gel directly on participant's skin on the area of the torso. Research staff will position the participant's body on the exam table to assure the liver can be located, placing the small probe on the body's surface (skin with gel) and begin recording images of the participant's liver.~The procedure will take 15-30 minutes, depending on the ease with which the research staff is able to accurately locate the participant's liver.~Results from the FibroScan will be discussed with a trained provider.
Study: NCT01309659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iron sucrose
Description: Patients will receive intravenous iron sucrose preparation at a dose of 200 mg per week through a peripheral intravenous catheter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iron sucrose
Description: Following 12 weeks of observation patients will receive intravenous iron sucrose preparation at a dose of 200 mg per week through a peripheral intravenous catheter.
Study: NCT03757533

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: 10 phone calls with a trained health coach

Intervention type: OTHER
Group type: OTHER
Intervention: Surveys
Description: Surveys to assess Behavioural and Psychosocial measures

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys
Description: Surveys to assess Behavioural and Psychosocial measures
Study: NCT01996800

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Manipulative Therapy (SMT)
Description: Spinal manipulation is a therapeutic intervention performed on spinal articulations which are synovial joints. These articulations in the spine that are amenable to spinal manipulative therapy include the z-joints, the atlanto-occipital, atlanto-axial, lumbosacral, sacroiliac, costotransverse and costovertebral joints.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Manipulative Therapy (SMT)
Description: Spinal manipulation is a therapeutic intervention performed on spinal articulations which are synovial joints. These articulations in the spine that are amenable to spinal manipulative therapy include the z-joints, the atlanto-occipital, atlanto-axial, lumbosacral, sacroiliac, costotransverse and costovertebral joints.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SMT and Neuromuscular Reeducation
Description: Neuromuscular reeducation is a general term that refers to techniques that attempt to retrain the neuromuscular system to function properly. The basis of this idea is that the formation of certain patterns of communication between muscles and nerves allow people to perform simple everyday acts such as climbing stairs.
Study: NCT04010396

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling: 1 EDTA and 1 Serum vial

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling: 1 EDTA and 1 Serum vial
Study: NCT00977951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intradermal avotermin
Description: 50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 3 and again on day 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intradermal avotermin
Description: 50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 5 and again on day 6

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle)
Description: Placebo administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 3 and again on day 4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 5 and again on day 6
Study: NCT01967199

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus-eluting balloon expandable stent
Description: Everolimus-eluting balloon expandable stent (Xience Prime or Xience Xpedition or Xience Alpine)
Study: NCT02989415

Intervention type: OTHER
Intervention: Mechanical Ventilation
Description: Mechanical ventilation during robotic surgery
Study: NCT01857661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sound generator
Description: hearing aid with an integrated sound generator

Intervention type: DEVICE
Group type: OTHER
Intervention: hearing aids with only amplification
Study: NCT02024542

Intervention type: OTHER
Intervention: Surgery
Description: Patients wishing to participate in the research will complete all necessary pre-operative work-up labs, testing \& counseling, complete and sign the informed consent. During weight loss surgery a small amount of subcutaneous and omental fat will be collected for analysis, with subsequent blood collection post surgery for analysis.

Intervention type: OTHER
Intervention: Surgery
Description: Patients wishing to participate in the research will complete all necessary pre-operative work-up labs, testing \& counseling, complete and sign the informed consent. During weight loss surgery a small amount of subcutaneous and omental fat will be collected for analysis, with subsequent blood collection post surgery for analysis.
Study: NCT04517747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: chemotherapy i.v.
Study: NCT01967199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: paclitaxel eluting balloon
Description: paclitaxel eluting balloon (SeQuent Please)
Study: NCT04517747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS 102
Description: p.o. twice daily
Study: NCT03571646

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Capnostream 20 monitoring
Description: Continuous monitoring on a general ward

Intervention type: DEVICE
Group type: OTHER
Intervention: PM1000N-RR monitoring
Description: Continuous monitoring on a general ward
Study: NCT00189930

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA-nef
Description: 3 imm.: 5E8_TCID50 MVA-nef, 1E8_TCID50 MVA-nef in non-dominant upper arm

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA-nef
Description: 3 imm.: 5E8_TCID50 MVA-nef, 1E8_TCID50 MVA-nef in non-dominant upper arm

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IMVAMUNE
Description: 3 immunizations: 1E8_TCID50 IMVAMUNE
Study: NCT04069858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switching to Generic Entecavir (Baracle®)
Description: switching to Baracle® 1 mg (generic drug) in chronic hepatitis B patients taking Baraclude® 1 mg (brand drug)
Study: NCT02764736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Patients will be given 20mg atorvastatin daily for 12 weeks and then increased to 40mg atorvastatin daily for an additional 12 weeks.
Study: NCT00522353

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oligofructose
Description: 21 grams per day in distributed over 3 doses per day for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7.89 grams of placebo maltodextrin divided into 3 equal doses per day for 3 months
Study: NCT00801879

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin calcium ointment, 2%
Description: 0.25 g in each nostril twice daily for 5 days (given monthly for up to 8 months)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ointment
Description: Placebo ointment 0.25g in each nostril twice daily for 5 days (repeated monthly for up to 8 months)
Study: NCT00612235

Intervention type: DRUG
Intervention: Lamotrigine
Description: Subjects had at least 3 months on a stable dosage of lamotrigine monotherapy.

Intervention type: DRUG
Intervention: Levetiracetam
Description: Subjects had at least 3 months on a stable dosage of levetiracetam monotherapy.

Intervention type: DRUG
Intervention: Carbamazepine
Description: Subjects had at least 3 months on a stable dosage of carbamazepine monotherapy.

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention was given
Study: NCT04948918

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anatomically optimized distal renal denervation
Description: Bilateral radiofrequency renal denervation will be performed using Symplicity Spyral renal denervation system. Generally, at least two separate applications of radiofrequency energy will be performed in each segmental branch of renal artery. Each application will be done through 4 electrodes deployed in helical manner according to the design of the catheter
Study: NCT04925232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation device
Description: Five days a week for 2 consecutive weeks, participants will have repetitive TMS at specific paramaters
Study: NCT02590588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib daily until unacceptable toxicity or disease progression.
Study: NCT02362958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib and capecitabine or vinorelbine
Description: lapatinib 1250 mg qd and Capecitabine 1000 mg/m2 bid or Vinorelbine 25mg/m2(d1,d8)
Study: NCT01138241

Intervention type: OTHER
Intervention: Tc99mDTPA renal clearance
Description: Tc99mDTPA renal clearance only for 200 patients~1. Plasma and urine 24 hr for creatinin, glucose, Creatinin clearance, Phosphatemia, uric acid, HCO3, protein, Microalbuminuria, ß2- microglobulinuria~2. serum creatinine prior and during TDF~3. TDF plasma levels ( only TDF use) using a validated high-performance liquid chromatography (HPLC)-mass method and stored PBMC for intracellular TDF levels~4. stored samples (PBMC) for pharmacogenomic study of transporter gene ie Organic Acid Transporter (OAT)~5. serum for cystanin C ( stored sample prior taking ARV and present time)~6. intensive 24 hours pharmacokinetic study of TDF in 20 patients
Study: NCT01743755

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone tablet 6 mg, once daily for four consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet, once daily for four consecutive days
Study: NCT03098823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAYOS
Description: FDA approved RAYOS for indication of fatigue in Lupus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: FDA approved corticosteroid frequently used for SLE.
Study: NCT01441037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danazol
Description: Danazol, 800 mg daily by mouth for 2 years
Study: NCT00763815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Self-administered by subcutaneous injections once daily within the hour preceding breakfast.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Self-administered by subcutaneous injections once daily within the hour preceding breakfast.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen auto-injector

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pen auto-injector

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Dose to be kept stable.
Study: NCT01138241

Intervention type: OTHER
Intervention: Tc99mDTPA renal clearance
Description: Tc99mDTPA renal clearance only for 200 patients~1. Plasma and urine 24 hr for creatinin, glucose, Creatinin clearance, Phosphatemia, uric acid, HCO3, protein, Microalbuminuria, ß2- microglobulinuria~2. serum creatinine prior and during TDF~3. TDF plasma levels ( only TDF use) using a validated high-performance liquid chromatography (HPLC)-mass method and stored PBMC for intracellular TDF levels~4. stored samples (PBMC) for pharmacogenomic study of transporter gene ie Organic Acid Transporter (OAT)~5. serum for cystanin C ( stored sample prior taking ARV and present time)~6. intensive 24 hours pharmacokinetic study of TDF in 20 patients

Intervention type: OTHER
Intervention: Tc99mDTPA renal clearance
Description: Tc99mDTPA renal clearance only for 200 patients~1. Plasma and urine 24 hr for creatinin, glucose, Creatinin clearance, Phosphatemia, uric acid, HCO3, protein, Microalbuminuria, ß2- microglobulinuria~2. serum creatinine prior and during TDF~3. TDF plasma levels ( only TDF use) using a validated high-performance liquid chromatography (HPLC)-mass method and stored PBMC for intracellular TDF levels~4. stored samples (PBMC) for pharmacogenomic study of transporter gene ie Organic Acid Transporter (OAT)~5. serum for cystanin C ( stored sample prior taking ARV and present time)~6. intensive 24 hours pharmacokinetic study of TDF in 20 patients
Study: NCT00218413

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NicVAX
Description: 100 μg, Formulation A, on Days 0, 21, 42, 91 \& 182
Study: NCT00763815

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone
Description: Dose to be kept stable.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin, if given to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin, if given to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
Study: NCT00218413

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NicVAX
Description: 200 μg, Formulation A, on Days 0, 21, 42, 91 \& 182
Study: NCT00886301

Intervention type: PROCEDURE
Group type: OTHER
Intervention: liver biopsy
Description: liver biopsy
Study: NCT00678405

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathlessness Intervention Service
Description: Breathlessness Intervention Service (BIS) consists of a clinical specialist physiotherapist \& palliative care consultant. It aims to manage the symptom of breathlessness in patients with any disease (cancer \& non-cancer) using a rehabilitative approach. Interventions include: evidence-based non-pharmacological interventions (psychological, social \& physical); palliative care input (e.g. end of life issues, psychosocial issues, family concerns); \& pharmacological review. Thus BIS seeks to enhance the self-management of breathlessness. Uniquely, care is located in clinic or in patients' own homes, as appropriate. Referrals come from medical specialists, GPs \& allied health professionals (with medical consent).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Best supportive care (Standard Care)
Description: Standard care: specialist outpatient appointments in secondary care (e.g. respiratory, cardiology, neurology or oncology) which may include specialist nurse input, and primary care services.
Study: NCT01202656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: One infusion of G-CSF 300 units administered by intrauterine infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: G-CSF
Description: One infusion of G-CSF 300 units administered by intrauterine infusion
Study: NCT00218413

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NicVAX
Description: 200 μg, Formulation B, on Days 0, 21, 42m 91 \& 182

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NicVAX
Description: 300 μg, Formulation B, on Days 0, 21, 42, 91 \& 182

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NicVAX
Description: 400 μg, Formulation B, on Days 0, 21, 42, 91 \& 182
Study: NCT01202656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: intrauterine saline infusion 1 cc

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: intrauterine saline infusion 1 cc
Study: NCT04986462

Intervention type: PROCEDURE
Intervention: shoulder arthroscopy
Description: Patients underwent ubacromial bursectomy and acromioplasty , cuff debridement and cuff repair, side to side suture of rotator cuff combined with suture anchor.
Study: NCT04153721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Name Digital Solution
Description: The digital solution offers a pre-operative program of information (pathology, treatment modalities, protocols to be followed) and training (stress management, psychological support, optional: nutritional preparation, physical exercise, reduction of alcohol and tobacco consumption).~In the post-operative phase, patients must daily assess their state of health (temperature, weight, wound, nausea / vomiting, urine / stool) and well-being (physical, moral, sleep, pain), from day 1 to day 7 after discharge, to facilitate the detection of complications by the medical team